Clearside closes patient enrolment in Phase II Dogwood trial of CLS-TA to treat macular edema

US clinical-stage biopharmaceutical firm Clearside Biomedical has completed patient enrolment in its Phase II clinical trial (Dogwood) of CLS-TA, its proprietary form of triamcinolone acetonide, to treat macular edema associated with non-infectious u…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news